Lead Product(s): Tree MATA MPL
Therapeutic Area: Immunology Product Name: Tree MATA MPL
Highest Development Status: Phase III Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergens ordinance time frame.
Lead Product(s): Rigerimod
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Avion Pharmaceuticals
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Agreement February 06, 2020
Avion and ImmuPharma to meet with the FDA in Q1 2020 to discuss guidance on a new optimised international Phase III trial protocol.